Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias Français
"This technology marks a significant advancement in how we care for patients with heart rhythm disorders—particularly those who previously had few viable cardiac resynchronization therapy treatment options," said Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI. "At the Texas Cardiac Arrhythmia Institute, our commitment is to bring the most advanced, evidence-based therapies to patients worldwide, and as a result of Dr. Canby's leadership, we successfully delivered on that promise."
The system is the first-ever to stimulate the heart muscle electrically via a small, leadless device—about the size of a grain of rice—that is implanted inside tissue of the left ventricle, the heart's primary pumping chamber. The device converts ultrasound energy into electrical pulses, restoring the heart's normal rhythm and pumping efficiency.
Traditional cardiac resynchronization therapies involve leads—thin and soft insulated wires about the size of a spaghetti noodle. This left ventricular endocardial pacing device provides a direct approach, which enables more flexible placement and expands access to those who were previously considered untreatable.
TCAI is a state-of-the-art Electrophysiology Center that includes six labs equipped with advanced technology where a group of esteemed cardiac electrophysiologists—led by Dr. Natale, a world-renowned expert in the field—perform a high volume of the most complex electrophysiology procedures.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
3 hours ago
- Cision Canada
Cognizant's AI Lab Records 59th U.S. Patent, Continuing to Generate AI Breakthroughs
In 2025, the Lab has yielded two new U.S. Granted Patents, open-sourced a key AI development platform, and earned a Gold Award from GECCO TEANECK, N.J., July 24, 2025 /CNW/ -- Cognizant (Nasdaq: CTSH) today announced that its AI Lab has been granted two new U.S. patents and a gold award for a research paper on "Realizing Human Expertise through AI" presented this month at GECCO (Genetic and Evolutionary Computation Conference) in Malaga, Spain. "Being granted two new U.S. patents in the first half of 2025—bringing our AI Lab's U.S. total to 59 with 23 more patents pending—underscores our relentless pace of innovation," said Babak Hodjat, CTO of AI at Cognizant. "Couple this with a Gold Award at GECCO and these milestones reflect our deep commitment to pioneering transformative AI technologies and turning cutting-edge ideas into real-world impact." The two latest patents highlight key innovations from Cognizant's AI research: U.S. Patent No. 12,282,845 (issued on April 22, 2025) covers a method for Multi-objective Coevolution of Deep Neural Network Architectures, aimed at improving model performance and resource efficiency. The method's application ranges from medical image classification to natural language processing. U.S. Patent No. 12,292,944 (issued on May 6, 2025) outlines a method for optimizing loss functions through Taylor Series Expansion, aiming to improve training efficiency and enhance model robustness, especially is data-limited scenarios. 1 These innovations, developed by Cognizant's researchers including Dr. Jason Liang, Dr. Elliot Meyerson and Professor Risto Miikkulainen, reinforce Cognizant's leadership in pushing the boundaries of AI and machine learning. To make the promise of artificial intelligence both more practical and broadly accessible, earlier this year, Cognizant's AI Lab open sourced its Neuro AI Multi-Agent Accelerator. Neuro AI helps businesses accelerate their development and adoption of AI agents, transforming their business processes for adaptive operations, real-time decision-making, and personalized customer experiences tailored to client-defined objectives and oversight. The Cognizant AI Lab, which opened its San Francisco-based flagship AI research facility in March 2024, has also been honored with the Gold Award for Human-Competitive Results at GECCO 2025 for its groundbreaking work on RHEA (Realizing Human Expertise through AI). Developed by Dr. Elliott Meyerson and Professor Risto Miikkulainen RHEA employs evolutionary AI to distill and recombine hundreds of models generated by human expert teams—most notably those submitted to the XPRIZE Pandemic Response Challenge—into refined decision strategies. In a rigorous evaluation, RHEA surpassed the performance of individual human submissions, realizing the latent potential even in incompletely developed human ideas, resulting in innovative pandemic policy recommendations. This milestone underlines Cognizant's leadership in harnessing global human expertise to drive next‑generation AI solutions. Risto Miikkulainen, VP of Research and Professor of Computer Science at UT Austin, said, "RHEA is a powerful example of how evolutionary AI can amplify global human intelligence—not just by matching expert solutions, but by going beyond them to discover novel, high-impact strategies. This recognition by the Humies Award committee reinforces the promise of population-based AI as a foundation for solving the world's most complex challenges." About Cognizant Cognizant (Nasdaq: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we're improving everyday life. See how at or @cognizant. About the Cognizant AI Lab The mission of the Cognizant AI Lab is to maximize human potential with Decision AI, a form of AI that combines generative AI, multi-agent architecture, deep learning, and evolutionary AI to create sophisticated decision-making systems. Decision AI powers Cognizant's Neuro ® AI platform, which is utilized by Fortune 500 companies and non-profits to discover new ways to exceed their goals. The platform enables organizations to rapidly build AI that optimizes decision-making, leading to revenue growth and societal progress. Led by AI pioneers Babak Hodjat and Risto Miikkulainen, the lab collaborates with institutions, academia, and technology partners to develop groundbreaking AI solutions responsibly. With over 120 patents (issued or pending) globally, the lab excels at combining scientific innovation with commercial application. It supports Cognizant's goal of improving everyday life, focusing on business and AI-for-good applications.
Cision Canada
4 hours ago
- Cision Canada
FILAMENT HEALTH ANNOUNCES TWO PHASE 2 RESEARCH TRIALS IN PARTNERSHIP WITH UNIVERSITY COLLEGE LONDON
UCL will study PEX010, the company's botanical psilocybin drug candidate, in trials investigating human perception, cognition, and therapeutic optimization VANCOUVER, BC, July 24, 2025 /CNW/ - Filament Health Corp. (OTC: FLHLF) (" Filament" or the " Company"), a clinical‐stage natural psychedelic drug development company, today announced that it has partnered with University College London (UCL) to supply its botanical psilocybin drug candidate, PEX010, for two phase 2 research trials. The Medicines and Healthcare Products Regulatory Agency (MHPRA)-approved trials will explore the effects of PEX010 on brain function, perception, and psychological wellbeing. "These studies represent two important frontiers in psychedelic research," said Dr. Jeremy I Skipper, Principal Investigator for both trials and Professor at UCL. "We will examine both how preparation methods influence therapeutic and cognitive outcomes, and how psilocybin interacts with sensory and cognitive systems to shape perception. Together, these studies offer valuable insight into the therapeutic potential and fundamental mechanisms of psychedelic compounds. They would not be possible without the support of Filament Health." The first of the two trials, led by Rosalind McAlpine, is a randomised controlled study evaluating the impact of the Digital Intervention for Psychedelic Preparation, a novel 21-day self-guided programme designed to enhance therapeutic outcomes of psychedelic experiences. Participants are randomly assigned to one of two structured preparatory pathways: a meditation-based intervention or a music-based control condition, both delivered through the same digital platform. Following the 21-day programme, all participants undergo a supervised 25 mg psilocybin session at UCL. The study aims to assess how different preparatory strategies influence the quality of the psychedelic experience, levels of psychological readiness, and changes in mental wellbeing. In addition to these outcomes, the trial evaluates intervention adherence, user engagement, and the acceptability of the digital platform - informing the design of future large-scale efficacy trials. The second trial, led by Oris Shenyan, Amplifying Experimentall y Induced Hallucinations With "Micro" Doses of Psilocybin, will explore how low doses of psilocybin affect the perception of geometric hallucinations and pareidolia, which is the tendency to see meaningful patterns in ambiguous stimuli – such as seeing faces in clouds. Building on models of excitatory visual cortex dynamics, the study will assess how low dose psilocybin-induced neural excitation interacts with external sensory input to shape hallucinatory experiences under controlled conditions. "Understanding how preparation style and dose affect the psychedelic experience is vital for advancing safe, effective psychedelic therapies," said Benjamin Lightburn, Chief Executive Officer and Co‐Founder at Filament Health. "We are proud to support these pioneering studies at one of the world's preeminent research institutions." PEX010 is authorized for investigation in 53 clinical trials worldwide for 14 mental health indications. ABOUT FILAMENT HEALTH (OTC:FLHLF) Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates. Learn more at and on X, Instagram, and LinkedIn. FORWARD LOOKING INFORMATION Certain statements and information contained in this press release and the documents referred to herein may constitute "forward‐looking statements" and "forward‐looking information," respectively, under Canadian securities legislation. Generally, forward‐looking information can be identified by the use of forward‐looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify forward‐looking statements or information. The forward‐looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward‐looking statements. Forward‐looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward‐looking statements or forward‐looking information, including the timing and results of clinical trials, the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholders approvals; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the proposed business combination; other expectations and assumptions concerning the transactions contemplated in the proposed business combination; the available funds of the parties and the anticipated use of such funds; the availability of financing opportunities; legal and regulatory risks inherent in the psychedelic drug development industry; risks associated with economic conditions, dependence on management and currency risk; risks relating to U.S. regulatory landscape; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the psychedelic drug development industry; risks related to the economy generally; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcement of judgments and effect service outside of Canada; and risks related to future acquisitions or dispositions. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐ looking statements and forward‐looking information. Filament will not update any forward‐looking statements or forward‐looking information that are incorporated by reference herein, except as required by applicable securities laws.
Cision Canada
4 hours ago
- Cision Canada
/R E P E A T -- MEDIA ADVISORY - Minister Michel to participate in an event hosted by Foundation for Black Communities in Montréal/ Français
GATINEAU, QC, July 23, 2025 /CNW/ - The Minister of Health, the Honourable Marjorie Michel, will deliver remarks at the Black Ideas Grant (B.I.G) 2.0 event in Montréal. Minister Michel is attending on behalf of the Honourable Patty Hajdu, Minister of Jobs and Families and Minister responsible for the Federal Economic Development Agency for Northern Ontario. Please note that all details are subject to change. Date: Thursday, July 24, 2025 Time: 5:15 p.m. EDT Place: N/A & CO Inc. 9494 Saint- Laurent Boulevard, Suite 1020 (10 th floor) Montréal, Quebec Notes for media: To register, contact [email protected] with your name and media outlet. Follow us on X (Twitter)
